This CellCept® Co-pay Program is valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD), TRICARE or any other federal or state government program (collectively, “Government Programs”) to pay for their medications are not eligible. The program is not valid for medications that are eligible to be reimbursed in their entirety by private insurance plans or other programs.
Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all remaining out-of-pocket expenses. The amount of the program’s benefits cannot exceed the patient’s out-of-pocket expenses for the cost of the drug fees associated with CellCept. The program benefit will reset every January 1st. This program is not health insurance or a benefit plan. The program does not obligate the use of any specific product or provider. Patients receiving assistance from charitable free medicine programs (such as the Genentech® Access to Care Foundation) or any other charitable organizations for the same expenses covered by the program are not eligible. The co-pay benefit cannot be combined with any other rebate, free trial or similar offer for the medication. No party may seek reimbursement for all or any part of the benefit received through this program.
The program may be accepted by participating pharmacies, physicians’ offices or hospitals. Once a patient is enrolled, this program will not honor claims with date of service or medication dispensing that precede program enrollment date by more than 180 days. Claims must be submitted within 365 days from the date of service unless otherwise indicated. Use of this program must be consistent with all relevant health insurance requirements. Participating patients, pharmacies, physician offices and hospitals are responsible for reporting the receipt of all program benefits as required by any insurer or by law. Program benefits may not be sold, purchased, traded or offered for sale.
The patient or their guardian must be 18 years or older to receive program assistance. This program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. Eligible patients will be automatically re-enrolled in the program on an annual basis. Eligible patients will be removed from the program after 3 years of inactivity (e.g., no claims submitted in a 3-year timeframe). Program eligibility and automatic re-enrollment are contingent upon the patient’s ability to meet all requirements set forth by the program. Healthcare providers may not advertise or otherwise use the program as a means of promoting their services or Genentech’s products to patients. Genentech reserves the right to rescind, revoke or amend the program without notice at any time.
Increased risk of loss of a pregnancy (miscarriage) and higher risk of birth defects. Females who take CellCept during pregnancy have a higher risk of miscarriage during the first 3 months (first trimester), and a higher risk that their baby will be born with birth defects.
The purpose of this registry is to gather information about the health of you and your baby.
Increased risk of getting certain cancers. People who take CellCept have a higher risk of getting lymphoma, and other cancers, especially skin cancer. Tell your doctor if you have:
Increased risk of getting serious infections. CellCept weakens the body’s immune system and affects your ability to fight infections. Serious infections can happen with CellCept and can lead to hospitalizations and death. These serious infections can include:
Call your doctor right away if you have any of the following signs and symptoms of infection:
See “What are the possible side effects of CellCept?” for information about other serious side effects.
Do not take CellCept if you are allergic to mycophenolate mofetil or any of the ingredients in CellCept.
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Some medicines may affect the way CellCept works, and CellCept may affect how some medicines work.
Especially tell your doctor if you take:
Know the medicines you take. Keep a list of them to show to your doctor or nurse and pharmacist when you get a new medicine. Do not take any new medicine without talking with your doctor.
Your doctor will do blood tests before you start taking CellCept and during treatment with CellCept to check your blood cell counts. Tell your doctor right away if you have any signs of infection (see “What is the most important information I should know about CellCept?”), including any unexpected bruising or bleeding. Also, tell your doctor if you have unusual tiredness, lack of energy, dizziness or fainting.
The most common side effects of CellCept include:
Side effects that can happen more often in children than in adults taking CellCept include:
These are not all of the possible side effects of CellCept. Tell your doctor about any side effect that bothers you or that does not go away. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.
Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide, for additional Important Safety Information.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.